All Stories

  1. Correction: Prisciandaro et al. Anatomical Versus Non-Anatomical Pulmonary Metastasectomy: European Multicentre Analysis. Cancers 2026, 18, 1037
  2. Refining Risk Stratification and Surveillance Strategies in Pleuropulmonary Solitary Fibrous Tumors—An International, Retrospective, Multicenter Analysis
  3. Establishment and Validation of Patient-Derived Non-Small Cell Lung Cancer Organoids as In Vitro Lung Cancer Models
  4. Preventive Aortic Stent Graft Implantation Prior to Thoracic Surgery: Early and Midterm Results
  5. Outcome Analysis of Treatment Modalities for Thoracic Sarcomas
  6. Change in Right-to-Left Shunt Fraction in Patients with Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Endarterectomy
  7. Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma
  8. Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results
  9. Cullin 4B Ubiquitin Ligase Is Important for Cell Survival and Regulates TGF-β1 Expression in Pleural Mesothelioma
  10. Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
  11. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  12. Acute on Chronic Thromboembolic Pulmonary Hypertension: Case Series and Review of Management
  13. Ex Vivo Lung Perfusion with β-Nicotinamide Adenine Dinucleotide (NAD+) Improves Ischemic Lung Function
  14. Dual-Energy CT Pulmonary Angiography for the Assessment of Surgical Accessibility in Patients with Chronic Thromboembolic Pulmonary Hypertension
  15. Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma
  16. Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry
  17. Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer
  18. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT
  19. Primary Lung Cancer Organoids for Personalized Medicine—Are They Ready for Clinical Use?
  20. Ex Vivo Lung Perfusion with K(ATP) Channel Modulators Antagonize Ischemia Reperfusion Injury
  21. Perfluorocarbon-Based Oxygen Carriers and Subnormothermic Lung Machine Perfusion Decrease Production of Pro-Inflammatory Mediators
  22. Subnormothermic Ex Vivo Lung Perfusion Temperature Improves Graft Preservation in Lung Transplantation
  23. Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma
  24. Introduction of a national multidisciplinary CTEPH board to improve operability assessment
  25. Molecular Research in Chronic Thromboembolic Pulmonary Hypertension
  26. Chronic thromboembolic pulmonary hypertension
  27. Intraluminal EWSR1-CREB1 gene rearranged, low-grade myxoid sarcoma of the pulmonary artery resembling extraskeletal myxoid chondrosarcoma (EMC)
  28. Moderne Aspekte der Lungenkrebschirurgie
  29. Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis
  30. Surgery in Malignant Pleural Mesothelioma
  31. Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
  32. Dynamic magnetic resonance imaging as an outcome predictor for lung-volume reduction surgery in patients with severe emphysema†
  33. Improved postoperative lung function after sublobar resection of non-small-cell lung cancer combined with lung volume reduction surgery in patients with advanced emphysema
  34. Lung volume reduction surgery beyond the NETT selection criteria
  35. Pleural mesothelioma: is the surgeon still there?
  36. Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery
  37. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation
  38. Heterogeneity in Malignant Pleural Mesothelioma
  39. Mediastinitis After Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration of a Follicular Dendritic Cell Sarcoma
  40. Lung volume reduction surgery in selected patients with emphysema and pulmonary hypertension†
  41. Influence of inter-observer delineation variability on radiomics stability in different tumor sites
  42. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
  43. Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
  44. Single-center experience with intraoperative extracorporeal membrane oxygenation use in lung transplantation
  45. Outcome After Lung Volume Reduction Surgery in Patients With Severely Impaired Diffusion Capacity
  46. Lung Transplantation with Controlled Donation after Circulatory Death Donors
  47. Lung transplantation in the elderly: Influence of age, comorbidities, underlying disease, and extended criteria donor lungs
  48. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
  49. Previous lung volume reduction surgery does not negatively affect survival after lung transplantation†
  50. Management des pulmonalarteriellen Sarkoms
  51. Treatment of limited disease small cell lung cancer: the multidisciplinary team
  52. A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma
  53. A benchmarking project on the quality of previous guidelines about the management of malignant pleural effusion from the European Society of Thoracic Surgeons (ESTS) Pleural Diseases Working Group
  54. Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients†
  55. Curative resection for lung cancer in octogenarians is justified
  56. Current practices in the management of malignant pleural effusions: a survey among members of the European Society of Thoracic Surgeons
  57. The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation
  58. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
  59. Extracorporeal Life Support as Bridge to Lung Retransplantation: A Multicenter Pooled Data Analysis
  60. Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group
  61. Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
  62. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study
  63. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma
  64. Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma
  65. Clinical Relevance of Our Multimodality Prognostic Score
  66. Impact of time interval between donor brain death and cold preservation on long-term outcome in lung transplantation
  67. MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD
  68. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
  69. Surgical Treatment after Chemotherapy in Malignant Pleural Mesothelioma
  70. Favorable outcome of children and adolescents undergoing lung transplantation at a European adult center in the new era
  71. Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s
  72. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
  73. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma
  74. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma
  75. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis
  76. Surgery versus SABR for resectable non-small-cell lung cancer
  77. Hedgehog Signaling in Malignant Pleural Mesothelioma
  78. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery
  79. Induction Therapy for Mesothelioma
  80. Use of Computed Tomography and Positron Emission Tomography/Computed Tomography for Staging of Local Extent in Patients With Malignant Pleural Mesothelioma
  81. Repeated lung volume reduction surgery is successful in selected patients
  82. Corrigendum to ‘Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know’
  83. Extrapleural Pneumonectomy After Induction Chemotherapy: Perioperative Outcome in 251 Mesothelioma Patients From Three High-Volume Institutions
  84. Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma†
  85. GAS5 long non-coding RNA in malignant pleural mesothelioma
  86. Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know
  87. CD74: a new prognostic factor for patients with malignant pleural mesothelioma
  88. A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
  89. European guidelines on structure and qualification of general thoracic surgery
  90. Multimodal management of malignant pleural mesothelioma: where are we today?
  91. PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy
  92. Perioperative Diclofenac Application during Video-Assisted Thoracic Surgery Pleurodesis Modulates Early Inflammatory and Fibrinolytic Processes in an Experimental Model
  93. Long-term outcomes of bilateral lobar lung transplantation
  94. Minimally invasive resection of thymomas with the da Vinci(R) Surgical System
  95. Diagnostik und Therapie des malignen Pleuramesothelioms - von der Palliationzur kurativen Intention
  96. Role of Hedgehog Signaling in Malignant Pleural Mesothelioma
  97. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma
  98. Sleeve resections with unprotected bronchial anastomoses are safe even after neoadjuvant therapy
  99. Pleural mesothelioma side populations have a precursor phenotype
  100. Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer
  101. Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model
  102. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
  103. Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: A preclinical study
  104. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis
  105. Editorial commentMay cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
  106. Pulmonary Kaposi's sarcoma after heart transplantation: a case report
  107. Prognostic significance of epithelial–mesenchymal transition in malignant pleural mesothelioma☆☆☆
  108. Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass
  109. Multimodality Strategies in Malignant Pleural Mesothelioma
  110. Functional inactivation of NF2/merlin in human mesothelioma
  111. Malignant pleural mesothelioma
  112. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting☆
  113. Autologous fibrin sealant reduces the incidence of prolonged air leak and duration of chest tube drainage after lung volume reduction surgery: A prospective randomized blinded study
  114. PTEN expression is a strong predictor of survival in mesothelioma patients☆
  115. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma
  116. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment☆
  117. Incidence of clinical pulmonary embolism after laparoscopic surgery
  118. Instillation of Taurolidine/Heparin after Laparotomy Reduces Intraperitoneal Tumour Growth in a Colon Cancer Rat Model
  119. Influence of Intraperitoneal Application of Taurolidine/Heparin on Expression of Adhesion Molecules and Colon Cancer in Rats Undergoing Laparoscopy
  120. Risk Factors for Perioperative Complications in Patients Undergoing Laparoscopic Cholecystectomy: Analysis of 22,953 Consecutive Cases from the Swiss Association of Laparoscopic and Thoracoscopic Surgery Database
  121. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma☆
  122. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma
  123. Preclinical Comparison of mTHPC and Verteporfin for Intracavitary Photodynamic Therapy of Malignant Pleural Mesothelioma
  124. Bleeding remains a major complication during laparoscopic surgery: analysis of the SALTS database
  125. Intraoperative photodynamic therapy of the chest cavity in malignant pleural mesothelioma bearing rats
  126. The influence of adhesion prophylactic substances and taurolidine/heparin on local recurrence and intraperitoneal tumor growth after laparoscopic-assisted bowel resection of colon carcinoma in a rat model
  127. Esophageal Necrosis and Perforation of the Left Main Bronchus Following Photodynamic Therapy of Esophageal Carcinoma
  128. Rekonstruktion der aorto- iliacalen Etage und Resektion maligner Tumoren - ein- oder zweizeitiges Vorgehen?
  129. Laparoscopic esophagogastrostomy: an alternative minimally invasive treatment for achalasia stage III
  130. Intragastrale Penetration eines justierbaren Magenbands
  131. Symptomatisches Aneurysma der Arteria gastroepiploica dextra Fallbericht und Literaturübersicht
  132. Inguinal Hernia Repair in the New Millennium: Plug and Patch Repair with Local Anesthesia
  133. Das Aneurysma der Vena femoralis als Differentialdiagnose der Schenkelhernie